11:51 AM EDT, 07/14/2025 (MT Newswires) -- Kenvue ( KVUE ) on Monday named an interim chief executive, while the consumer health company said it reviewing strategic alternatives aimed at enhancing shareholder value.

Kenvue ( KVUE ), the maker of products like Tylenol and Listerine, appointed current director Kirk Perry as interim CEO, effective immediately. He succeeds Thibaut Mongon, who has departed the company.

The company is exploring strategic options, including optimizing its brand portfolio.

"The board's strategic review is underway, and we are considering a broad range of potential alternatives, including ways to simplify the company's portfolio and how it operates," Kenvue Chair Larry Merlo said. "At the same time, with the CEO transition and recent appointment of a new CFO, we are aligning leadership expertise to drive the company forward."

In May, Kenvue ( KVUE ) announced the appointment of Amit Banati as its chief financial officer.

The company, which will release its second-quarter results on Aug. 7, said it expects to report adjusted earnings per share of $0.28 to $0.29 on a 4% decline projected in net sales. Analysts polled by FactSet forecast non-GAAP EPS of $0.28 and sales of $3.93 billion. The company reported adjusted EPS of $0.32 and net sales of $4 billion in the year-earlier quarter.

The company in May forecast flat EPS this year due to the estimated impact of tariffs and foreign exchange.

Shares of Kenvue ( KVUE ) were up 0.9% intraday Monday.

Price: 21.50, Change: +0.16, Percent Change: +0.73